Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer

Basit Öğe Kaydı
dc.authorid0000-0001-9481-6307
dc.contributor.authorYavas, Guler.
dc.contributor.authorYavas, Cagdas.
dc.date.accessioned2020-03-26T20:19:20Z
dc.date.available2020-03-26T20:19:20Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroductionIn recent years, there has been undoubted progress in the evaluation and development of targeted agents for non-small cell lung cancer (NSCLC). At the same time, remarkable progress in radiation therapy (RT) has been developed largely due to our ability to more effectively focus and deliver radiation to the tumor target volume. Both developments brought the idea of combining the radiation with molecularly targeted agents in order to improve outcomes in NSCLC patients who have limited survival times with standard chemoradiotherapy.MethodsWe identified patients with gastric cancer treated with post-operative radiation at our institution between 2002 and 2016. Acute and late toxicities were evaluated per RTOG/EORTC Radiation Toxicity Grading Scale. Statistical analysis was performed using Chi-square tests, t tests, log-rank, and logistic regression.ResultsCetuximab has no survival benefit, and it seems to be toxic in this patient population. Bevacizumab has severe toxicity including tracheoesophageal fistulae formation in addition to its ineffectiveness. It is difficult to have an opinion about TKIs when combined with RT since most of the studies were conducted on unselected patients. For oligometastatic/oligoprogressive NSCLC patients, it seems to be reasonable to use a combined regimen since combined regimen resulted in superior survival time; however, the patients should be followed up closely with respect to the toxicity. In patients with brain metastases, the use of concomitant RT + TKIs increased survival with acceptable toxicity levels.ConclusionsIn this review, we summarize the recent literature about the use of molecularly targeted agents with concurrent RT in NSCLC patients.en_US
dc.identifier.citationYavas, G., Yavas, C. (2019). Targeted Therapy Combined with Thoracic Radiotherapy for Non-Small Cell Lung Cancer. Journal of Radiation Oncology, 8(1), 1-12.
dc.identifier.doi10.1007/s13566-019-00379-xen_US
dc.identifier.endpage12en_US
dc.identifier.issn1948-7894en_US
dc.identifier.issn1948-7908en_US
dc.identifier.issue1en_US
dc.identifier.pmid#YOKen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s13566-019-00379-x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38219
dc.identifier.volume8en_US
dc.identifier.wosWOS:000463671300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorYavas, Guler.
dc.institutionauthorYavas, Cagdas.
dc.language.isoenen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.relation.ispartofJOURNAL OF RADIATION ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChemoradiotherapyen_US
dc.subjectEGFR inhibitorsen_US
dc.subjectTargeted therapyen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectRadiotherapyen_US
dc.subjectTargeted therapyen_US
dc.titleTargeted therapy combined with thoracic radiotherapy for non-small cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
Guler YAVAS.pdf
Boyut:
320.65 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
Ä°ndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Radyasyon Onkolojisi/Makale Koleksiyonu